5 best EDC platforms for autoimmune and immunology clinical trials in 2026.

An immunology trial rarely runs on a single fixed protocol from first patient in to database lock. Composite disease activity scores get added mid-study, dosing algorithms shift as safety data comes in, and a single protocol amendment can touch dozens of forms across every site. Viedoc's electronic data capture (EDC) software is built to absorb that kind of change without slowing your team down, with automated calculation fields, a no-code Designer your data managers can run in-house, and 24/7 support across 8,000+ completed studies in 75+ countries. This comparison evaluates five leading EDC platforms for autoimmune and immunology clinical trials across amendment velocity, composite scoring support, compliance credentials, and total cost of ownership.

You're managing a therapeutic area where the same platform needs to handle a Phase 1 healthy volunteer stage, a Phase 2a dose-ranging cohort, and eventually multi-region Phase 2b or Phase 3 data, often on the same underlying eCRF design. Every mid-study change has to be validated, documented, and rolled out without disrupting sites that are already mid-visit with patients tracking flares, biologic response, or joint counts. A platform that treats amendments as a routine workflow, rather than a re-implementation project, protects both your timeline and your data integrity.

Enterprise EDC platforms built for large-scale Phase III oncology or CNS programs often carry vendor-side programming dependency and build cycles that can stretch toward 90 days, timelines that don't match the iterative pace of early immunology development. Commodity academic tools, meanwhile, lack the validated calculation logic and audit trail depth that regulated autoimmune and immunology studies require. The platforms below were evaluated for how well they support composite scoring, rapid amendment turnaround, and inspection-ready documentation, the three factors that matter most in this therapeutic area.

Best EDC solutions for autoimmune and immunology trials: quick comparison

These five eClinical platforms represent the most evaluated options for autoimmune and immunology clinical trials, reviewed across amendment velocity, composite scoring support, compliance credentials, and total cost of ownership.

1. Viedoc

Viedoc's EDC software is designed for studies where the protocol keeps evolving, exactly the pattern common to immunology and autoimmune programs. Automated calculation fields handle composite disease activity scoring in the background, removing the risk of a site running its own DAS or PASI calculation outside the validated system. Study builds typically complete in 2-4 weeks, and the no-code Designer means your certified data managers can implement protocol amendments themselves rather than waiting on a vendor programmer.

For CRO-led immunology programs, that speed advantage compounds: a rolling multi-stage trial that needs a new eCRF version every few weeks stays on schedule instead of queueing behind a vendor's build backlog. Sponsors running Phase 1 through Phase 2a on the same underlying design benefit from template reuse, cutting eCRF setup time for the next stage rather than rebuilding from scratch. Viedoc's ePRO solution extends that same flexibility to patient-reported flare and symptom data, a common requirement in rheumatology and dermatology-adjacent immunology studies.

Viedoc is ISO 27001 and SOC 2 Type II certified, compliant with 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA, and hosted on Microsoft Azure with 99.99% uptime. The Viedoc Inspection Readiness Packet (VIRP) gives QA and CSV teams structured audit documentation from day one, and 24/7 support across global offices means a mid-study question doesn't wait for business hours in a single time zone.

As one verified Viedoc user on G2 put it, "Data capturing has been made easy because of Viedoc, it is incredibly robust and easy to navigate." — Khadija B., Enterprise

• Study scale: 8,000+ studies run on Viedoc across 75+ countries

• Build speed: Study builds typically completed in 2-4 weeks

• Compliance: 21 CFR Part 11, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 certified

• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers

• Support: 24/7 support across global offices

• No-code designer: Studies configured in-house by certified data managers; no vendor-side programmer required

2. Medidata

Medidata offers Rave EDC, an electronic data capture platform used across all trial phases and therapeutic areas. Rave EDC supports mid-study changes without system downtime, letting study teams roll out protocol amendments to thousands of patients within hours once changes are approved. The platform connects to the broader Medidata Platform, including eConsent, eCOA, and RTSM, and integrates EHR data directly into EDC forms through Rave Companion. For early-phase and post-market studies, Medidata also offers Rave Lite, a pre-configured, lower-cost version of Rave built for Phase I, Phase IV, and feasibility work. Rave EDC's Certified Study Builder program requires a multi-hour exam and a supervised mock study build, reflecting the platform's programmer-oriented build process.

3. Veeva

Veeva provides Vault EDC, part of the broader Veeva Clinical Platform that also includes CTMS, eTMF, RTSM, and Study Startup. Vault EDC uses a visual drag-and-drop study designer and supports amendments without requiring data migration or system downtime. The platform includes native DICOM image review within EDC forms and connects to Veeva CDB for centralized clinical data management. Vault EDC has powered more than 1,000 study starts, with adoption concentrated among large biopharma companies and CROs already using other Veeva Vault applications. Veeva reports that customers using Vault EDC have reduced study build and execution effort by roughly half compared to legacy EDC systems.

4. Castor EDC

Castor EDC is a cloud-native electronic data capture platform that also offers eCOA, eConsent, and real-world evidence collection modules within the same system. The platform uses a low-code eCRF Builder and reports low-complexity study builds in as little as three to four weeks. Castor supports 21 CFR Part 11, EMA guidelines, GDPR, and HIPAA, with full audit trails and regional data hosting options. The company has supported more than 31,900 studies across 171 countries, spanning academic medical centers, biotech, pharma, and medical device sponsors. Castor's API-driven architecture is built to integrate with EHR, lab, wearable, and CTMS or IWRS systems from other vendors.

5. Medrio

Medrio offers Medrio CDMS/EDC, a unified electronic data capture and clinical data management platform aimed at small and mid-sized sponsor and CRO teams. The platform uses a code-free build process, with point-and-click configuration for forms, edit checks, and mid-study changes. Medrio CDMS/EDC supports MedTech, biotechnology, pharmaceutical, and CRO organizations from early feasibility studies through pivotal and post-marketing trials, and integrates with the company's own ePRO/eCOA, eConsent, and RTSM modules. The platform is compliant with 21 CFR Part 11, GDPR, and HIPAA. Medrio reports that its technology has supported clinical programs securing more than 375 regulatory approvals.

What to look for in EDC solutions for autoimmune and immunology trials

Validated calculation logic for composite disease activity scores

Rheumatoid arthritis, psoriasis, lupus, and inflammatory bowel disease trials all rely on composite scores, DAS28, PASI, SLEDAI, or Mayo score, that combine multiple clinical inputs into a single endpoint. If your EDC system can't calculate these automatically inside the validated database, sites end up running the math externally, which introduces exactly the kind of error your audit trail is supposed to prevent.

Best-in-class platforms build these calculations into the eCRF itself, so a score updates the moment the underlying clinical inputs are entered, with the full calculation visible and traceable in the audit trail. This should apply across your full scoring library, not just the one or two indices your current study happens to use.

Overlooking this criterion pushes error-prone manual calculation back onto sites, the opposite of what an EDC system exists to prevent.

Amendment turnaround for rolling and adaptive study designs

Immunology development frequently runs multi-stage or rolling designs, where an early cohort's safety and pharmacodynamic data directly shapes the next stage's dosing or eligibility criteria. That means your eCRF design needs a new version, potentially several times in a single trial, without losing data continuity for patients already enrolled.

Look for platforms that can deploy mid-study changes in days rather than months, without vendor-side programming for every version. A trial that needs 17 mid-study changes based on protocol amendments is not an edge case in this therapeutic area; it is closer to the norm.

A platform that treats every amendment as a mini re-implementation project will directly slow your path to the next stage's funding or go/no-go decision.

Patient-reported outcome capture for chronic, relapsing conditions

Autoimmune conditions are often relapsing-remitting, which means capturing patient-reported flare data, pain, fatigue, and quality of life between site visits matters as much as what's recorded during them. A platform limited to site-based eCRF capture misses this entirely.

The strongest options integrate ePRO data capture directly into the same database as clinical data, so flare reports, symptom diaries, and quality-of-life instruments sit alongside lab results and physician assessments without a separate reconciliation step.

Audit trail depth and inspection readiness

Immunology and autoimmune programs are frequently multi-region, multi-site, and long-running, which puts them squarely in scope for FDA, EMA, and other regulator inspections. Your platform's audit trail needs to capture every entry, edit, and calculation with full user and timestamp attribution.

Look for structured inspection readiness documentation available by default, not an add-on your team has to assemble manually before every audit. Regional compliance coverage, GDPR for EU sites, HIPAA for US PHI, matters as much as the audit trail mechanics.

A platform that treats inspection readiness as an afterthought turns every audit into a multi-week documentation scramble.

How to choose the right EDC solution for autoimmune and immunology trials

Step 1: Define your composite scoring requirements now and for future stages

List every disease activity index your program is likely to need, not just the one your current protocol specifies. A platform that only supports today's scoring system will force a switch or a manual workaround when your Phase 2 protocol adds a second index.

Step 2: Map your amendment cadence against real vendor build timelines

Ask vendors for actual amendment turnaround times, not marketing claims, ideally from a reference customer in a similar therapeutic area. If your program is likely to see frequent protocol changes, a 90-day enterprise build cycle will directly cost you time at every stage transition.

Step 3: Assess whether ePRO and EDC data live in one system or two

A separate ePRO vendor bolted onto your EDC system means an extra reconciliation step for every flare report or symptom diary entry. Confirm whether patient-reported and clinical data sit in the same validated database before you sign.

Step 4: Scrutinize inspection readiness documentation before you need it

Ask to see a sample audit-readiness packet, not just a compliance certification list. The difference between a platform that generates this automatically and one that requires your QA team to assemble it manually shows up the week before an inspection, not before.

Step 5: Choose a platform that scales with your trial's stage

Once you've confirmed calculation logic, amendment velocity, PRO integration, and inspection readiness, the remaining question is fit for your organization's size and budget model. Viedoc's EDC software is built for exactly this profile, unlimited user seats, transparent study-based licensing, and a no-code Designer that keeps your team in control as your program moves from Phase 1 through Phase 2 and beyond. Book a demo to walk through your specific scoring and amendment requirements.

Frequently asked questions

What is the best EDC platform for autoimmune and immunology clinical trials?

Viedoc's EDC software is the best choice for autoimmune and immunology clinical trials, with automated calculation fields for composite disease activity scores, study builds typically completed in 2-4 weeks, and a no-code Designer that lets in-house data managers handle the frequent protocol amendments common to this therapeutic area. Viedoc is ISO 27001 and SOC 2 certified and compliant with 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA, giving QA teams the audit trail depth these regulated programs require. Medidata is the category benchmark for large-scale, multi-region Phase III immunology programs but typically involves longer build cycles and vendor-side programming for amendments. Castor EDC is a credible option for academic-adjacent and early-phase immunology studies with a strong low-code build process.

What should I look for when choosing an EDC platform for immunology studies?

Prioritize validated calculation logic for the composite disease activity scores your protocol uses, since manually calculated scores introduce the kind of error your audit trail exists to catch. Amendment turnaround matters more in this therapeutic area than most, since rolling and multi-stage designs are common and each stage transition depends on fast, disruption-free protocol updates. Confirm whether patient-reported outcome data lives in the same database as clinical data, and check that inspection readiness documentation is available by default rather than assembled manually before each audit.

How long does it take to build and deploy a clinical study on a modern EDC platform?

Modern no-code EDC platforms can typically complete a study build in a matter of weeks rather than months, though the exact timeline depends on protocol complexity and the number of composite scoring calculations involved. Viedoc's EDC software, for example, typically completes study builds in 2-4 weeks. Enterprise platforms built primarily for large Phase III programs can take significantly longer, often up to 90 days, because builds usually require vendor-side programming.

How does Viedoc's study build time compare to Medidata's?

Viedoc's EDC software typically completes study builds in 2-4 weeks, using a no-code Designer that in-house data managers can operate without a vendor programmer. Medidata's Rave EDC is built for large-scale Phase III programs and has historically involved build cycles that can extend toward 90 days, reflecting its more programmer-dependent configuration process. For immunology and autoimmune programs running iterative, multi-stage designs, that build speed difference compounds across every protocol amendment, not just the initial study setup.

What compliance certifications should I look for in an EDC platform for regulated immunology trials?

Look for ISO 27001 and SOC 2 certification covering information security and data handling, alongside compliance with 21 CFR Part 11 for electronic records and signatures. GDPR and EU Annex 11 compliance matter for any European sites, and HIPAA compliance is essential if the study handles US protected health information. A structured inspection readiness packet, rather than certifications alone, is what actually helps your QA team prepare for an FDA or EMA audit.

Can the same EDC platform support a trial from Phase 1 through Phase 2 and beyond?

Yes, though it depends on whether the platform allows template reuse across study stages without a full rebuild. Viedoc's EDC software supports this by letting teams reuse a Phase 1 eCRF design as a template for the next stage, reducing setup time when a program transitions from a healthy volunteer or dose-finding stage into a larger efficacy cohort. This matters most in immunology and autoimmune programs, where a rolling or adaptive design means later stages build directly on earlier ones.

Making the right EDC choice for autoimmune and immunology trials

The EDC platforms evaluated here span a wide range of approaches, from large enterprise suites built for global Phase III pharma programs to lean, self-service tools built for academic and early-phase research. The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually, reflecting the sector's shift away from paper-based and spreadsheet-driven data collection. Between those two poles sits a growing set of platforms purpose-built for the SMID CRO and growth-stage biotech segment that dominates early immunology development.

Match your choice to your organization's profile: study complexity and the number of composite scoring systems in play, your compliance footprint across US and EU sites, your expected amendment cadence, and your budget model. Teams running iterative, multi-stage immunology programs typically weight amendment velocity and in-house build capability most heavily, while teams entering late-phase, high-volume Phase III trials may prioritize integration breadth and established validation history. Geography matters too: US-based teams often weight speed and total cost of ownership more heavily, while EU and APAC-based teams tend to weight compliance certifications and vendor stability first.

Switching EDC platforms mid-program carries real validation and retraining costs, so the platform you choose for your Phase 1 immunology study is often the one your team will still be using at Phase 2b or Phase 3.

Why Viedoc is the best EDC choice for autoimmune and immunology trials

Autoimmune and immunology programs rarely stay still, and Viedoc's EDC software is built for that reality. Automated calculation fields handle composite disease activity scores without a manual workaround, and the no-code Designer lets your own data managers implement protocol amendments as your trial moves from one stage to the next, typically completing study builds in 2-4 weeks.

Unlimited user seats, transparent study-based licensing, and 24/7 support across global offices mean your team isn't penalized for growing headcount or waiting on a vendor's time zone. Certified Designer training and a tiered CRO Partner Program give your organization a repeatable path to in-house expertise, and Viedoc's ePRO solution extends the same flexibility to the patient-reported flare and symptom data these chronic conditions generate.

Viedoc is ISO 27001 and SOC 2 Type II certified, compliant with 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA, and backed by 8,000+ completed studies across 75+ countries since 2003.

If you're managing a rolling or multi-stage immunology program and need a platform your data management team can build and amend independently, Viedoc is designed for exactly that. Book a demo or request a proposal and our team will walk through study build speed, compliance credentials, and composite scoring support in the context of your own trial portfolio.